Table 2.

Ongoing Trials in BC.

Trial	Phase	Population	Arms
NCT03959891	I	HR+/HER2−	Fulvestrant + Ipatasertib vs. Aromatase Inhibitor + Ipatasertib vs. Fulvestrant + Ipatasertib + Palbociclib
NCT04060862	IB-III	HR+/HER2−	Stage 3: ipatasertib + palbociclib + fulvestrant vs. placebo + palbociclib + fulvestrant
NCT03337724	III	TNBC	ipatasertib + paclitaxel vs. placebo + paclitaxel
NCT03280563	IB-II	HR+/HER2−	Stage 1: Atezolizumab + Ipatasertib + Fulvestrant vs. Atezolizumab + Ipatasertib vs. Atezolizumab + Fulvestrant vs. Atezolizumab + Entinostat vs. Fulvestrant (placebo)Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy
NCT03800836	I	TNBC	In Cohort 1: ipatasertib + atezolizumab + paclitaxel (nab-paclit) +/− antra
NCT03424005	IB-II	TNBC	Stage 1: Atezolizumab + Nab-Paclitaxel +/− Tocilizumab vs. Nab-Paclitaxel vs. Atezolizumab + Sacituzumab GovitecanStage 2: Capecitabine vs. Atezolizumab + Ipatasertib vs. Atezolizumab + SGN-LIV1A vs. Atezolizumab + Selicrelumab + Bevacizumab vs. tezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)
NCT03395899	II	HR+/HER2−	Atezolizumab vs. Atezolizumab + Cobimetinib vs. Atezolizumab + Ipatasertib vs. Atezolizumab + Ipatasertib + Bevacizumab
NCT02390427	I	HER2+	Taselisib + Pertuzumab + Trastuzumab + Paclitaxel vs. Taselisib + Pertuzumab + Trastuzumab vs. Taselisib + Trastuzumab emtansine + Pertuzumab vs. Taselisib + Trastuzumab emtansine
NCT02167854	I	HER2+	Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
NCT04208178	III	HER2+	Study of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)

Abbreviations: human epidermal growth factor receptor-2 positive (HER2+), hormone receptor positive (HR+), triple-negative breast cancer (TNBC).